We produce institutional quality equity research on small/midcap healthcare and life sciences companies, making it available to all investors wherever they are based. Our goal is to bring exciting investment ideas to investors, and to assist companies in achieving their objectives.
14
Research Clients
135
Reports published
10k+
Readers in database
Paper in @Cancers_MDPI shows Angle PLC's @Parsortix system can be used to characterise #melanoma cells so patients receive better therapies, and identify if a patient has relapsed before standard imaging techniques can do so
.@BGenBio announce that 1st cohort of Phase II NSCLC trial with bemcentinib in combination with Keytruda has met its primary endpoint with ORR>25%. Data to be published at #SITC19. $BGBIO.OL shares up 5%
https://t.co/Vk2VcpVO23
.@MaxCyte_info has initiated the third cohort of the Phase I study with its first CARMA therapy MCY-M11. The treatment is being well tolerated and the feasibility of the 1-day manufacturing process has been confirmed. Read our note at https://t.co/yGpMKaLOfv
The offer period for @NexstimOyj's warrant offering (fully underwritten) has opened and the company aims to place additional shares at the same time. Overall, c €2.8m net should be raised, extending its cash runway into Q320. Read our note at
https://t.co/DKgtKvYekJ
.@NexstimOyj continues to gain momentum with the launch of its NBT system for the treatment of depression (#MDD). Read our note on Nexstim following its Q3 trading update at https://t.co/DKgtKvYekJ
Selectivity of @HChiMed TKIs supports exploring combination approaches to improve treatment of solid tumours, & positively the global Innovent Biologics PD-1 collaboration has been expanded to include #surufatinib as well as #fruquintinib $HCM
https://t.co/MbwSVLk645
Please sign up here to be added to our distribution database
